The Committee for Medicinal products for Human Use (CHMP) decided that APTIVUS’ s benefits are greater than its risks in combination with low dose ritonavir for the treatment of HIV-1 infection in highly pre-treated adult patients with virus resistant to multiple protease inhibitors.